MedTrace Logo

Safety Evaluation of Aminophylline and Methazolamide

NCT01587027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-02-10

Study results available
· View outcomes & findings →

Summary

This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.

Conditions

  • Mountain Sickness

Interventions

DRUG

Aminophylline

Aminophylline dosage form-tablet dosage-500mg

DRUG

Methazolamide

Methazolamide dosage form-tablet dosage-250mg

DRUG

Aminophylline and Methazolamide

Aminophylline 500mg orally and Methazolamide 250mg orally

Sponsors & Collaborators

  • Defense Advanced Research Projects Agency

    collaborator FED

  • University of Colorado, Denver

    collaborator OTHER

  • Poudre Valley Health System

    lead OTHER

Principal Investigators

  • Gary Luckasen, M.D. · Poudre Valley Health System

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01587027 on ClinicalTrials.gov